Fyarro (sirolimus protein-bound particles for injectable suspension (albumin-bound), 100 mg per vial, NDC 80803-153-50, manufactured for Aadi Bioscience, Inc, CA.

Failed Stability Specifications

Recall #: D-0059-2023
Affected scope: 2,333 vials
Initiated: October 13, 2022

Compiled from official public sources by the publisher. · Updated September 2026

Aadi Bioscience recalled Fyarro (sirolimus protein-bound particles for injectable suspension (albumin-bound), 100 … - a low-severity action.

Fyarro (sirolimus protein-bound particles for injectable suspension (albumin-bound), 100 … was recalled by Aadi Bioscience in November 23, 2022. Reason: Failed Stability Specifications. Check the official notice for the remedy. Verify recall #D-0059-2023 with the FDA Drug before acting.

The recall

Aadi Bioscience issued this low-severity FDA Drug recall-Failed Stability Specifications.

Low
severity level: Class III
classification: November 23, 2022
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-0059-2023 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This recall's affected scope, documented in the Recall Profile below, stays within a single-region or limited-distribution footprint. Distribution scope (see Distribution below) directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Where this agency-classified recall sits among FDA Class I/II/III notices

Of 88,244 recalls with an agency hazard classification, 19,068 are high severity, 64,652 moderate, and 4,524 low. A further 16,179 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified low severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Product description

Fyarro (sirolimus protein-bound particles for injectable suspension (albumin-bound), 100 mg per vial, NDC 80803-153-50, manufactured for Aadi Bioscience, Inc, CA.

Reason for recall

Failed Stability Specifications

Recall Profile

Structured summary of the FDA Drug recall record
Attribute	Value
Agency	U.S. Food and Drug Administration
Severity class	Low (Class III)
Status	Terminated
Recall number	D-0059-2023
Date reported	November 23, 2022
Date initiated	October 13, 2022
Recalling firm	Aadi Bioscience
Firm location	Pacific Palisades, CA
Affected scope	2,333 vials
Distribution	Within the U.S Market - PA, AL, KY, TN

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

Check the recall number (D-0059-2023) and product description against the item you own. Search the archive
Confirm the current status with FDA Drug before acting, recall details can be updated.
Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled? ▼

Fyarro (sirolimus protein-bound particles for injectable suspension (albumin-bound), 100 mg per vial, NDC 80803-153-50, manufactured for Aadi Bioscience, Inc, CA.. Recalled by Aadi Bioscience. Units affected: 2,333 vials.

Why was this product recalled? ▼

Failed Stability Specifications

Which agency issued this recall? ▼

This recall was issued by the FDA Drug on November 23, 2022. Severity: Low. Recall number: D-0059-2023.

Where was the recalled product distributed? ▼

Distribution: Within the U.S Market - PA, AL, KY, TN.

Should I stop using a recalled medication or medical device? ▼

Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nationwide recalls with similar severity or category timing

Drug and device notices outside this firm and state, matched by severity timing and product category.

Similar severity · nearest report date

Same archive severity grade (Low), closest by report date among other firms and states.

MED-RX UROLOGICAL CYSTO/BLADDER IRRIGATIO… 2022-11-23 Phenytoin Sodium Injection, USP 100 mg/2 … 2022-11-30 Phenytoin Sodium Injection, USP, 250 mg/5… 2022-11-30 Allergy Relief D, Fexofenadine HCL 60mg/A… 2022-12-07

Similar Dietary Supplements · nearest report date

Same product category, closest by report date among other firms and states (deduped against the severity set).

Seeking Health brand Optimal Multivitamin… 2022-10-26 Sprigs - Dental Health: Herbal Dietary Su… 2022-10-12 Sprigs - Honey Herbal Syrup: Herbal Dieta… 2022-10-12 Sprigs - Lil Ones Sleepy Time: Herbal Die… 2022-10-12

Compare this recall with Goody King Magnetic Building Cubes and Blocks Recalled Due … → · All Dietary Supplements recalls

This recall: FDA Drug, reported November 23, 2022. Severity classes follow each agency's own taxonomy; related-recall context is computed across the full archive.

Methodology · Corrections · Archive as of August 2026